Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$11.24 USD
-0.32 (-2.77%)
Updated Sep 19, 2025 03:59 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, Astellas Pharma Inc. has a market cap of $16.69B, which represents its share price of $9.22 multiplied by its outstanding shares number of 1.81B. As a large-cap company, ALPMY's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ALPMY 11.24 -0.32(-2.77%)
Will ALPMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
Other News for ALPMY
J.P. Morgan Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Astellas Pharma just downgraded at Bernstein, here's why
Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer